세계의 철 킬레이트 요법 시장 보고서(2025년)
Iron Chelation Therapy Global Market Report 2025
상품코드 : 1769629
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

철 킬레이트 요법 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 34억 6,000만 달러로 성장할 전망이며, CAGR 6.6%로 성장이 예측됩니다. 예측 기간 동안의 성장은 경구 킬레이션 치료제 사용 증가, 희귀질환 연구투자 증가, 개별화 치료 접근법의 중시 증가, 신규 치료에 대한 규제 당국의 승인 증가, 개발도상국에서의 헬스케어 접근성 개선 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 경구 킬레이트 약 제제의 진보, 병용요법 전략의 대두, 표적 약물 전달 기술의 혁신, 철과잉증을 검출하는 고도의 진단 도구 도입, 환자 중심의 치료 모델의 진화 등이 있습니다.

수혈 횟수 증가가 향후 수년간 철 킬레이트 요법 시장의 성장을 견인할 것으로 예측됩니다. 수혈이란 혈액량을 회복시키거나 빈혈이나 실혈 등의 병세를 치료하기 위해 제공된 혈액을 환자에게 투여하는 과정을 말합니다. 수혈의 증가는 주로 복잡한 외과 수술의 증가에 기인하고 있으며, 많은 경우 혈액 순환 동태의 안정을 유지하고 환자의 회복을 돕기 위해 수혈을 필요로 하는 큰 폭의 출혈로 이어집니다. 철 킬레이트 요법은 잦은 수혈의 결과로 체내에 축적되는 과도한 철분을 제거하기 위해 필수적입니다. 예를 들면, 미국을 거점으로 하는 비영리 단체인 미국 적십자사에 의하면, 미국에서는 연간 약 1,600만 개의 혈액 성분이 수혈되고 있습니다. 낫상적혈구증은 9만 명에서 10만 명에게 영향을 미치며, 매년 약 1,000명의 영아가 낫상적혈구증으로 태어나 그 대부분이 평생 수혈을 필요로 합니다. 그 결과 수혈 빈도의 증가가 철 킬레이트 요법 시장의 확대에 박차를 가하고 있습니다.

철 킬레이트 요법 시장의 주요 기업은 치료 효과를 높이고 부작용을 최소화하며 환자의 어드레싱을 향상시키기 위해 생체 이용률을 향상시킨 차세대 킬레이터 개발에 주력하고 있습니다. 이러한 선진적인 킬레이트제는 흡수성과 치료 효율을 높이도록 처방되고 있으며, 철 과잉증 관리에 있어 투여 레지멘을 합리화하고 컴플라이언스를 향상시키는 데 도움을 주고 있습니다. 예를 들어 2023년 3월 이탈리아 제약회사 Chiesi Farmaceutici S.p.A.는 1일 2회 복용하는 서방성 철 킬레이트제 FERRIPROX MR에 대해 사라세미아, 낫상 적혈구증, 기타 빈혈 환자의 철과잉증 치료제로 캐나다 보건부로부터 승인을 받았습니다. 본 제품은 희귀질환 치료에 있어 보다 높은 편의성과 지속적인 도움을 제공합니다. 페리플록스 MR 1,000mg은 임상시험에서 철과잉증 환자에게 양호한 안전성 프로파일을 보여 유효하고 안전한 것으로 증명되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Iron chelation therapy is a medical treatment aimed at eliminating excess iron from the body in patients who undergo frequent blood transfusions or suffer from iron overload disorders. This treatment uses chelating agents that bind to surplus iron, enabling its removal from the body through urine or feces. It is commonly used to manage conditions like thalassemia, sickle cell disease, and other chronic anemias to prevent organ damage and improve long-term health outcomes.

The primary types of iron chelation therapy include deferasirox, deferoxamine, and deferiprone. Deferasirox is an oral chelating agent widely used to reduce excess iron in patients receiving regular blood transfusions for conditions such as beta-thalassemia and other chronic anemias. The therapy can be administered via different routes, including oral, parenteral, intravenous, and subcutaneous. Key indications for its application include thalassemia, sickle cell disease, myelodysplastic syndromes (MDS), and non-transfusion-dependent thalassemia (NTDT). It is appropriate for a diverse patient group, encompassing pediatric, adult, elderly, and gender-specific populations, and is utilized across various settings such as hospitals, specialty clinics, homecare environments, and others.

The iron chelation therapy market research report is one of a series of new reports from The Business Research Company that provides iron chelation therapy market statistics, including the iron chelation therapy industry global market size, regional shares, competitors with the iron chelation therapy market share, detailed iron chelation therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the iron chelation therapy industry. This iron chelation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The iron chelation therapy market size has grown strongly in recent years. It will grow from $2.51 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing demand for safer iron removal treatments, rising global rates of blood transfusions, a growing number of chronic anemia cases linked to genetic disorders, increased healthcare spending in emerging markets, and expanding clinical research into iron chelation therapy options.

The iron chelation therapy market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The projected growth in the forecast period can be attributed to the rising use of oral chelation medications, increased investments in research for rare diseases, a growing emphasis on personalized treatment approaches, more regulatory approvals for novel therapies, and improved healthcare access in developing countries. Key trends anticipated during this period include advancements in oral chelation drug formulations, the emergence of combination therapy strategies, innovations in targeted drug delivery technologies, the introduction of advanced diagnostic tools for detecting iron overload, and the evolution of patient-centric treatment models.

The rising number of blood transfusions is expected to drive the growth of the iron chelation therapy market in the coming years. Blood transfusion refers to the process of administering donated blood to a patient to restore blood volume or treat medical conditions such as anemia or blood loss. The increase in blood transfusions is primarily attributed to the growing number of complex surgical procedures, which often lead to substantial blood loss requiring transfusion to maintain hemodynamic stability and aid in patient recovery. Iron chelation therapy is essential for eliminating excess iron that accumulates in the body as a result of frequent transfusions. For example, according to the American Red Cross, a U.S.-based nonprofit organization, approximately 16 million blood components are transfused annually in the U.S. Sickle cell disease impacts between 90,000 and 100,000 individuals, with nearly 1,000 infants born with the condition each year, many of whom require lifelong transfusions. As a result, the growing frequency of blood transfusions is fueling the expansion of the iron chelation therapy market.

Leading companies in the iron chelation therapy market are concentrating on the development of next-generation chelators with improved bioavailability to enhance treatment effectiveness, minimize adverse effects, and boost patient adherence. These advanced chelators are formulated to increase absorption and therapeutic efficiency, helping to streamline dosing regimens and promote better compliance in managing iron overload conditions. For example, in March 2023, Chiesi Farmaceutici S.p.A., an Italy-based pharmaceutical firm, received approval from Health Canada for FERRIPROX MR, an extended-release iron chelator taken twice daily, for the treatment of iron overload in patients with thalassemia, sickle cell disease, and other forms of anemia. This product offers greater convenience and sustained support for rare disease treatment. Clinical studies have demonstrated that FERRIPROX MR 1,000 mg is both effective and safe for the intended patient population, with a favorable safety profile for those with iron overload.

In September 2024, Mitem Pharma, a pharmaceutical company based in France, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed sum. This acquisition is intended to strengthen Mitem Pharma's position in the iron chelation therapy market and expand its portfolio with a proven treatment for managing iron overload conditions. Novartis AG, headquartered in Switzerland, is a pharmaceutical company that provides iron chelation therapy solutions.

Major players in the iron chelation therapy market are Pfizer Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Zydus Cadila, Balchem, Piramal Pharma Solutions, Vifor Pharma Group, MSN Laboratories, Natco Pharma Ltd., CTX Lifesciences, Nouryon, Tivan Sciences, and Synnat Pharma.

North America was the largest region in the iron chelation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron chelation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron chelation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The iron chelation therapy market includes revenues earned by entities by providing services such as clinical trial management, personalized treatment planning, drug development, and monitoring iron levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron chelation therapy market also includes sales of injectable iron chelators, extended-release formulations, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Iron Chelation Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on iron chelation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for iron chelation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iron chelation therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Iron Chelation Therapy Market Characteristics

3. Iron Chelation Therapy Market Trends And Strategies

4. Iron Chelation Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Iron Chelation Therapy Growth Analysis And Strategic Analysis Framework

6. Iron Chelation Therapy Market Segmentation

7. Iron Chelation Therapy Market Regional And Country Analysis

8. Asia-Pacific Iron Chelation Therapy Market

9. China Iron Chelation Therapy Market

10. India Iron Chelation Therapy Market

11. Japan Iron Chelation Therapy Market

12. Australia Iron Chelation Therapy Market

13. Indonesia Iron Chelation Therapy Market

14. South Korea Iron Chelation Therapy Market

15. Western Europe Iron Chelation Therapy Market

16. UK Iron Chelation Therapy Market

17. Germany Iron Chelation Therapy Market

18. France Iron Chelation Therapy Market

19. Italy Iron Chelation Therapy Market

20. Spain Iron Chelation Therapy Market

21. Eastern Europe Iron Chelation Therapy Market

22. Russia Iron Chelation Therapy Market

23. North America Iron Chelation Therapy Market

24. USA Iron Chelation Therapy Market

25. Canada Iron Chelation Therapy Market

26. South America Iron Chelation Therapy Market

27. Brazil Iron Chelation Therapy Market

28. Middle East Iron Chelation Therapy Market

29. Africa Iron Chelation Therapy Market

30. Iron Chelation Therapy Market Competitive Landscape And Company Profiles

31. Iron Chelation Therapy Market Other Major And Innovative Companies

32. Global Iron Chelation Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Iron Chelation Therapy Market

34. Recent Developments In The Iron Chelation Therapy Market

35. Iron Chelation Therapy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기